All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 63rd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Carrie Kitko, Vanderbilt University Medical Center, Nashville, US. We asked, Is axatilimab for chronic GvHD (cGvHD) well tolerated and what does the preliminary response data look like?
Is axatilimab for cGvHD well tolerated and what does the preliminary response data look like?
In this video, Kitko discusses the phase II AGAVE-201 trial (NCT04710576), which investigates the safety, tolerability, and efficacy of axatilimab in patients with cGvHD who have received at least two prior lines of systemic therapy.
Novel drugs for treating cGvHD: Phase I results of axatilimab for heavily pretreated patients
Second line or further lines of therapy represent an unmet need in treating patients with chronic graft-versus-host disease (cGvHD) due to disease...
Ruxolitinib treatment pre-, during-, and post-transplant for patients with MF
Myelofibrosis (MF) is clonal myeloproliferative disorder characterized by splenomegaly, bone marrow fibrosis, and risk of transformation to acute myeloid leukemia....
Subscribe to get the best content related to GvHD delivered to your inbox